The efficacy and safety of Desvenlafaxine Succinate Sustained-release Tablets in the prophylactic treatment of migraine

INTERVENTION: Topiramate:Topiramate Tablets (25 mg), 25 mg × 60 tablets/bottle. Starting at 25 mg/day, administered orally in two divided doses (i.e., twice daily), titrated w;Desvenlafaxine:Desvenlafaxine Succinate Extended?Release Tablets (50 mg), 50 mg × 14 tablets/box, taken orally once daily (QD) for 3 consecutive months of continuous; CONDITION: Migraine without aura PRIMARY OUTCOME: Mean change from baseline in monthly headache days (overall average);Change from baseline in mean and peak headache intensity (assessed by Visual Analogue Scale, VAS); SECONDARY OUTCOME: Number and types of serious adverse events (SAEs).;Change from baseline in the Generalized Anxiety Disorder 7?item (GAD?7) score.;monthly headache days (overall average);Change from baseline in the Migraine?Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) score.;Proportion of subjects achieving =50%, =75%, and 100% reduction in headache days from baseline.;Proportion of patients discontinuing treatment due to adverse events.;Change from baseline in the dose and frequency of acute attack medication use.;Change from baseline in the Headache Impact Test (HIT?6) score.;Change from baseline in the Patient Health Questionnaire?9 (PHQ?9) score.;Improvement from baseline in the Pittsburgh Sleep Quality Inde X(PSQI) score.;Number and types of adverse events (AEs).;Change from baseline in the Migraine Disability Assessment (MIDAS) score; INCLUSION CRITERIA: 1.Meet the diagnostic criteria for migraine according to the International Headache Society (ICHD‐3); 2.Aged 18–64 years, both males and females; 3.Experiencing 4 to 14 migraine attacks per month; 4.History of migraine attacks lasting more than 1 year.